Overcoming immune resistance mechanisms in patients with cancer is critical for successful immunotherapy. A new study now identifies LIMIT as an immunogenic long non-coding RNA (lncRNA) that intrinsically regulates anti-tumour immune responses, thereby highlighting the therapeutic potential of targeting lncRNAs to improve the outcome of cancer immunotherapy.
This is a preview of subscription content, log in via an institution to check access.
References
Frankish, A. et al. Nucleic Acids Res. 47, D766–D773 (2019).
Schmitt, A. M. & Chang, H. Y. Cancer Cell 29, 452–463 (2016).
Huarte, M. Nat. Med. 21, 1253–1261 (2015).
Gaopeng, L. et al. Nat. Cell Biol. https://doi.org/10.1038/s41556-021-00672-3 (2021).
Hezroni, H. et al. Cell Reports 11, 1110–1122 (2015).
Hu, Q. et al. Nat. Immunol. 20, 835–851 (2019).
Wang, Q. M., Lian, G. Y., Song, Y., Huang, Y. F. & Gong, Y. Life Sci. 231, 116335 (2019).
Gil, N. & Ulitsky, I. Nat. Rev. Genet. 21, 102–117 (2020).
Chen, Y. G., Satpathy, A. T. & Chang, H. Y. Nat. Immunol. 18, 962–972 (2017).
Zhang, L., Xu, X. & Su, X. Mol. Cancer 19, 48 (2020).
Carpenter, S. et al. Science 341, 789–792 (2013).
Kalbasi, A. & Ribas, A. Nat. Rev. Immunol. 20, 25–39 (2020).
Hou, J. et al. J. Immunother. Cancer 9, e001819 (2021).
Tawbi, H. et al. J. Clin. Oncol. 36, TPS9596 (2018).
Ribas, A. et al. Nat. Commun. 11, 6262 (2020).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Hou, J., Peng, W. LIMITing tumours with an immunogenic lncRNA. Nat Cell Biol 23, 443–445 (2021). https://doi.org/10.1038/s41556-021-00682-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41556-021-00682-1
- Springer Nature Limited